Advertisement

The Relationship Between Biological and Imaging Characteristics in Enhancing and Nonenhancing Glioma

  • Janine M. LupoEmail author
  • Javier E. Villanueva-Meyer
Chapter
First Online:

Abstract

Advanced MR imaging offers insights into the biological processes underpinning the enhancing and nonenhancing signal abnormality characteristic of glioma seen on routine MR imaging. Here we focus on physiologic and metabolic MR imaging techniques including diffusion, perfusion, and spectroscopy, as they relate to histopathology and molecular features of gliomas. The utility of these advanced techniques in evaluating glioma treatment response is also discussed.

Keywords

Glioma heterogeneity Image-guided tissue sampling Contrast-enhancing tumor Nonenhancing tumor Tumor biology 
This is a preview of subscription content, log in to check access.

References

  1. 1.
    Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Burger PC, Jouvet A, et al. The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol. 2007;114(2):97–109.PubMedPubMedCentralCrossRefGoogle Scholar
  2. 2.
    Carroll KT, Bryant AK, Hirshman B, Alattar AA, Joshi R, Gabel B, et al. Interaction between the contributions of tumor location, tumor grade, and patient age to the survival benefit associated with gross total resection (GTR). World Neurosurg. 2018;111:e790–8.PubMedCrossRefPubMedCentralGoogle Scholar
  3. 3.
    Chang SM, Nelson S, Vandenberg S, Cha S, Prados M, Butowski N, et al. Integration of preoperative anatomic and metabolic physiologic imaging of newly diagnosed glioma. J Neuro-Oncol. 2009;92(3):401–15.CrossRefGoogle Scholar
  4. 4.
    Ho VKY, Reijneveld JC, Enting RH, Bienfait HP, Robe P, Baumert BG, et al. Changing incidence and improved survival of gliomas. Eur J Cancer. 2014;50(13):2309–18.PubMedCrossRefPubMedCentralGoogle Scholar
  5. 5.
    Eckel-Passow JE, Lachance DH, Molinaro AM, Walsh KM, Decker PA, Sicotte H, et al. Glioma groups based on 1p/19q, IDH, and TERT promoter mutations in tumors. N Engl J Med. 2015;372(26):2499–508.PubMedPubMedCentralCrossRefGoogle Scholar
  6. 6.
    Cancer Genome Atlas Research Network, Brat DJ, Verhaak RGW, Aldape KD, Yung WKA, Salama SR, et al. Comprehensive, integrative genomic analysis of diffuse lower-grade Gliomas. N Engl J Med. 2015;372(26):2481–98.CrossRefGoogle Scholar
  7. 7.
    Louis DN, Perry A, Reifenberger G, von Deimling A, Figarella-Branger D, Cavenee WK, et al. The 2016 World Health Organization classification of tumors of the central nervous system: a summary. Acta Neuropathol. 2016;131(6):803–20.CrossRefGoogle Scholar
  8. 8.
    Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJB, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005;352(10):987–96.CrossRefGoogle Scholar
  9. 9.
    Coons SW, Johnson PC. Regional heterogeneity in the proliferative activity of human gliomas as measured by the Ki-67 labeling index. J Neuropathol Exp Neurol. 1993;52(6):609–18.PubMedCrossRefPubMedCentralGoogle Scholar
  10. 10.
    Parker NR, Khong P, Parkinson JF, Howell VM, Wheeler HR. Molecular heterogeneity in glioblastoma: potential clinical implications. Front Oncol. 2015;5:55.PubMedPubMedCentralGoogle Scholar
  11. 11.
    Pallud J, Varlet P, Devaux B, Geha S, Badoual M, Deroulers C, et al. Diffuse low-grade oligodendrogliomas extend beyond MRI-defined abnormalities. Neurology. 2010;74(21):1724–31.PubMedCrossRefGoogle Scholar
  12. 12.
    Duffau H. Long-term outcomes after supratotal resection of diffuse low-grade gliomas: a consecutive series with 11-year follow-up. Acta Neurochir. 2016;158(1):51–8.PubMedCrossRefGoogle Scholar
  13. 13.
    Crawford FW, Khayal IS, McGue C, Saraswathy S, Pirzkall A, Cha S, et al. Relationship of pre-surgery metabolic and physiological MR imaging parameters to survival for patients with untreated GBM. J Neuro-Oncol. 2009;91(3):337–51.CrossRefGoogle Scholar
  14. 14.
    Saraswathy S, Crawford FW, Lamborn KR, Pirzkall A, Chang S, Cha S, et al. Evaluation of MR markers that predict survival in patients with newly diagnosed GBM prior to adjuvant therapy. J Neuro-Oncol. 2009;91(1):69–81.CrossRefGoogle Scholar
  15. 15.
    Nelson SJ, Kadambi AK, Park I, Li Y, Crane J, Olson M, et al. Association of early changes in 1H MRSI parameters with survival for patients with newly diagnosed glioblastoma receiving a multimodality treatment regimen. Neuro-Oncology. 2017;19(3):430–9.PubMedPubMedCentralGoogle Scholar
  16. 16.
    Deviers A, Ken S, Filleron T, Rowland B, Laruelo A, Catalaa I, et al. Evaluation of the lactate-to-N-acetyl-aspartate ratio defined with magnetic resonance spectroscopic imaging before radiation therapy as a new predictive marker of the site of relapse in patients with glioblastoma multiforme. Int J Radiat Oncol Biol Phys. 2014;90(2):385–93.PubMedCrossRefPubMedCentralGoogle Scholar
  17. 17.
    Li Y, Lupo JM, Parvataneni R, Lamborn KR, Cha S, Chang SM, et al. Survival analysis in patients with newly diagnosed glioblastoma using pre- and postradiotherapy MR spectroscopic imaging. Neuro-Oncology. 2013;15(5):607–17.PubMedPubMedCentralCrossRefGoogle Scholar
  18. 18.
    Wen PY, Macdonald DR, Reardon DA, Cloughesy TF, Sorensen AG, Galanis E, et al. Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. J Clin Oncol. 2010;28(11):1963–72.PubMedPubMedCentralCrossRefGoogle Scholar
  19. 19.
    Ellingson BM, Bendszus M, Boxerman J, Barboriak D, Erickson BJ, Smits M, et al. Consensus recommendations for a standardized brain tumor imaging protocol in clinical trials. Neuro-Oncology. 2015;17(9):1188–98.PubMedPubMedCentralGoogle Scholar
  20. 20.
    Smits M. Imaging of oligodendroglioma. Br J Radiol. 2016;89(1060):20150857.PubMedPubMedCentralCrossRefGoogle Scholar
  21. 21.
    Scott JN, Brasher PMA, Sevick RJ, Rewcastle NB, Forsyth PA. How often are nonenhancing supratentorial gliomas malignant? A population study. Neurology. 2002;59(6):947–9.PubMedCrossRefGoogle Scholar
  22. 22.
    Shahar T, Rozovski U, Marko NF, Tummala S, Ziu M, Weinberg JS, et al. Preoperative imaging to predict intraoperative changes in tumor-to-corticospinal tract distance: an analysis of 45 cases using high-field intraoperative magnetic resonance imaging. Neurosurgery. 2014;75(1):23–30.PubMedCrossRefGoogle Scholar
  23. 23.
    Fudaba H, Shimomura T, Abe T, Matsuta H, Momii Y, Sugita K, et al. Comparison of multiple parameters obtained on 3T pulsed arterial spin-labeling, diffusion tensor imaging, and MRS and the Ki-67 labeling index in evaluating glioma grading. AJNR Am J Neuroradiol. 2014;35(11):2091–8.PubMedCrossRefPubMedCentralGoogle Scholar
  24. 24.
    Yan J-L, van der Hoorn A, Larkin TJ, Boonzaier NR, Matys T, Price SJ. Extent of resection of peritumoral diffusion tensor imaging-detected abnormality as a predictor of survival in adult glioblastoma patients. J Neurosurg. 2017;126(1):234–41.PubMedCrossRefGoogle Scholar
  25. 25.
    Coenen VA, Krings T, Mayfrank L, Polin RS, Reinges MH, Thron A, et al. Three-dimensional visualization of the pyramidal tract in a neuronavigation system during brain tumor surgery: first experiences and technical note. Neurosurgery. 2001;49(1):86–92; discussion 92.PubMedGoogle Scholar
  26. 26.
    Byrnes TJD, Barrick TR, Bell BA, Clark CA. Diffusion tensor imaging discriminates between glioblastoma and cerebral metastases in vivo. NMR Biomed. 2011;24(1):54–60.PubMedCrossRefGoogle Scholar
  27. 27.
    Essig M, Nguyen TB, Shiroishi MS, Saake M, Provenzale JM, Enterline DS, et al. Perfusion MRI: the five most frequently asked clinical questions. AJR Am J Roentgenol. 2013;201(3):W495–510.PubMedCrossRefGoogle Scholar
  28. 28.
    Griffith B, Jain R. Perfusion imaging in neuro-oncology: basic techniques and clinical applications. Radiol Clin N Am. 2015;53(3):497–511.PubMedCrossRefGoogle Scholar
  29. 29.
    Cha S, Tihan T, Crawford F, Fischbein NJ, Chang S, Bollen A, et al. Differentiation of low-grade oligodendrogliomas from low-grade astrocytomas by using quantitative blood-volume measurements derived from dynamic susceptibility contrast-enhanced MR imaging. AJNR Am J Neuroradiol. 2005;26(2):266–73.PubMedPubMedCentralGoogle Scholar
  30. 30.
    Cha S, Lupo JM, Chen MH, Lamborn KR, McDermott MW, Berger MS, et al. Differentiation of glioblastoma multiforme and single brain metastasis by peak height and percentage of signal intensity recovery derived from dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging. AJNR Am J Neuroradiol. 2007;28(6):1078–84.PubMedCrossRefPubMedCentralGoogle Scholar
  31. 31.
    Law M, Young RJ, Babb JS, Peccerelli N, Chheang S, Gruber ML, et al. Gliomas: predicting time to progression or survival with cerebral blood volume measurements at dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging. Radiology. 2008;247(2):490–8.PubMedPubMedCentralCrossRefGoogle Scholar
  32. 32.
    Jain R. Measurements of tumor vascular leakiness using DCE in brain tumors: clinical applications. NMR Biomed. 2013;26(8):1042–9.PubMedCrossRefPubMedCentralGoogle Scholar
  33. 33.
    Roberts HC, Roberts TPL, Ley S, Dillon WP, Brasch RC. Quantitative estimation of microvascular permeability in human brain tumors: correlation of dynamic Gd-DTPA-enhanced MR imaging with histopathologic grading. Acad Radiol. 2002;9(Suppl 1):S151–5.PubMedCrossRefPubMedCentralGoogle Scholar
  34. 34.
    Roberts HC, Roberts TP, Brasch RC, Dillon WP. Quantitative measurement of microvascular permeability in human brain tumors achieved using dynamic contrast-enhanced MR imaging: correlation with histologic grade. AJNR Am J Neuroradiol. 2000;21(5):891–9.PubMedGoogle Scholar
  35. 35.
    Di N, Yao C, Cheng W, Ren Y, Qu J, Wang B, et al. Correlation of dynamic contrast-enhanced MRI derived volume transfer constant with histological angiogenic markers in high-grade gliomas. J Med Imaging Radiat Oncol. 2018;  https://doi.org/10.1111/1754-9485.12701.CrossRefGoogle Scholar
  36. 36.
    Patankar TF, Haroon HA, Mills SJ, Balériaux D, Buckley DL, Parker GJM, et al. Is volume transfer coefficient (K(trans)) related to histologic grade in human gliomas? AJNR Am J Neuroradiol. 2005;26(10):2455–65.PubMedGoogle Scholar
  37. 37.
    Watts JM, Whitlow CT, Maldjian JA. Clinical applications of arterial spin labeling. NMR Biomed. 2013;26(8):892–900.PubMedCrossRefPubMedCentralGoogle Scholar
  38. 38.
    Kim MJ, Kim HS, Kim JH, Cho KG, Kim SY. Diagnostic accuracy and interobserver variability of pulsed arterial spin labeling for glioma grading. Acta Radiol. 2008;49(4):450–7.PubMedCrossRefPubMedCentralGoogle Scholar
  39. 39.
    Furtner J, Bender B, Braun C, Schittenhelm J, Skardelly M, Ernemann U, et al. Prognostic value of blood flow measurements using arterial spin labeling in gliomas. PLoS One. 2014;9(6):e99616.PubMedPubMedCentralCrossRefGoogle Scholar
  40. 40.
    Qiao XJ, Ellingson BM, Kim HJ, Wang DJJ, Salamon N, Linetsky M, et al. Arterial spin-labeling perfusion MRI stratifies progression-free survival and correlates with epidermal growth factor receptor status in glioblastoma. AJNR Am J Neuroradiol. 2015;36(4):672–7.PubMedCrossRefPubMedCentralGoogle Scholar
  41. 41.
    Nelson SJ. Multivoxel magnetic resonance spectroscopy of brain tumors. Mol Cancer Ther. 2003;2(5):497–507.PubMedPubMedCentralGoogle Scholar
  42. 42.
    McKnight TR, von dem Bussche MH, Vigneron DB, Lu Y, Berger MS, McDermott MW, et al. Histopathological validation of a three-dimensional magnetic resonance spectroscopy index as a predictor of tumor presence. J Neurosurg. 2002;97(4):794–802.PubMedCrossRefPubMedCentralGoogle Scholar
  43. 43.
    Li Y, Larson P, Chen AP, Lupo JM, Ozhinsky E, Kelley D, et al. Short-echo three-dimensional H-1 MR spectroscopic imaging of patients with glioma at 7 Tesla for characterization of differences in metabolite levels. J Magn Reson Imaging. 2015;41(5):1332–41.PubMedCrossRefPubMedCentralGoogle Scholar
  44. 44.
    Dreher C, Oberhollenzer J, Meissner J-E, Windschuh J, Schuenke P, Regnery S, et al. Chemical exchange saturation transfer (CEST) signal intensity at 7T MRI of WHO IV° gliomas is dependent on the anatomic location. J Magn Reson Imaging. 2018;49(3):777–85.PubMedCrossRefPubMedCentralGoogle Scholar
  45. 45.
    Pepin KM, McGee KP, Arani A, Lake DS, Glaser KJ, Manduca A, et al. MR elastography analysis of glioma stiffness and IDH1-mutation status. AJNR Am J Neuroradiol. 2018;39(1):31–6.PubMedCrossRefPubMedCentralGoogle Scholar
  46. 46.
    Villanueva-Meyer JE, Barajas RF, Mabray MC, Chen W, Shankaranarayanan A, Koon P, et al. Differentiation of brain tumor-related edema based on 3D T1rho imaging. Eur J Radiol. 2017;91:88–92.PubMedPubMedCentralCrossRefGoogle Scholar
  47. 47.
    Chaumeil MM, Lupo JM, Ronen SM. Magnetic resonance (MR) metabolic imaging in glioma. Brain Pathol. 2015;25(6):769–80.PubMedCrossRefPubMedCentralGoogle Scholar
  48. 48.
    Harris RJ, Cloughesy TF, Liau LM, Prins RM, Antonios JP, Li D, et al. pH-weighted molecular imaging of gliomas using amine chemical exchange saturation transfer MRI. Neuro-Oncology. 2015;17(11):1514–24.PubMedPubMedCentralCrossRefGoogle Scholar
  49. 49.
    Herholz K. Brain tumors: an update on clinical PET research in gliomas. Semin Nucl Med. 2017;47(1):5–17.PubMedCrossRefPubMedCentralGoogle Scholar
  50. 50.
    Venneti S, Dunphy MP, Zhang H, Pitter KL, Zanzonico P, Campos C, et al. Glutamine-based PET imaging facilitates enhanced metabolic evaluation of gliomas in vivo. Sci Transl Med. 2015;7(274):274ra17.PubMedPubMedCentralCrossRefGoogle Scholar
  51. 51.
    Karavaeva E, Harris RJ, Leu K, Shabihkhani M, Yong WH, Pope WB, et al. Relationship between [18F]FDOPA PET uptake, apparent diffusion coefficient (ADC), and proliferation rate in recurrent malignant gliomas. Mol Imaging Biol. 2015;17(3):434–42.PubMedCrossRefGoogle Scholar
  52. 52.
    Barajas RF, Phillips JJ, Parvataneni R, Molinaro A, Essock-Burns E, Bourne G, et al. Regional variation in histopathologic features of tumor specimens from treatment-naive glioblastoma correlates with anatomic and physiologic MR imaging. Neuro-Oncology. 2012;14(7):942–54.PubMedPubMedCentralCrossRefGoogle Scholar
  53. 53.
    Elkhaled A, Jalbert LE, Phillips JJ, Yoshihara HAI, Parvataneni R, Srinivasan R, et al. Magnetic resonance of 2-hydroxyglutarate in IDH1-mutated low-grade gliomas. Sci Transl Med. 2012;4(116):116ra5.PubMedPubMedCentralCrossRefGoogle Scholar
  54. 54.
    Ferreira LMR. Cancer metabolism: the Warburg effect today. Exp Mol Pathol. 2010;89(3):372–80.PubMedCrossRefGoogle Scholar
  55. 55.
    Vander Heiden MG, Cantley LC, Thompson CB. Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science. 2009;324(5930):1029–33.PubMedPubMedCentralCrossRefGoogle Scholar
  56. 56.
    Strickland M, Stoll EA. Metabolic reprogramming in glioma. Front Cell Dev Biol. 2017;5:43.PubMedPubMedCentralCrossRefGoogle Scholar
  57. 57.
    Talasila KM, Røsland GV, Hagland HR, Eskilsson E, Flønes IH, Fritah S, et al. The angiogenic switch leads to a metabolic shift in human glioblastoma. Neuro-Oncology. 2017;19(3):383–93.PubMedGoogle Scholar
  58. 58.
    Jain R, Griffith B, Alotaibi F, Zagzag D, Fine H, Golfinos J, et al. Glioma angiogenesis and perfusion imaging: understanding the relationship between tumor blood volume and leakiness with increasing glioma grade. AJNR Am J Neuroradiol. 2015;36(11):2030–5.PubMedCrossRefPubMedCentralGoogle Scholar
  59. 59.
    Barajas RF, Phillips JJ, Vandenberg SR, McDermott MW, Berger MS, Dillon WP, et al. Pro-angiogenic cellular and genomic expression patterns within glioblastoma influences dynamic susceptibility weighted perfusion MRI. Clin Radiol. 2015;70(10):1087–95.PubMedCrossRefPubMedCentralGoogle Scholar
  60. 60.
    Shiroishi MS, Habibi M, Rajderkar D, Yurko C, Go JL, Lerner A, et al. Perfusion and permeability MR imaging of gliomas. Technol Cancer Res Treat. 2011;10(1):59–71.PubMedCrossRefPubMedCentralGoogle Scholar
  61. 61.
    Kickingereder P, Sahm F, Radbruch A, Wick W, Heiland S, Deimling A, et al. IDH mutation status is associated with a distinct hypoxia/angiogenesis transcriptome signature which is non-invasively predictable with rCBV imaging in human glioma. Sci Rep. 2015;5:16238.PubMedPubMedCentralCrossRefGoogle Scholar
  62. 62.
    Autry A, Phillips JJ, Maleschlijski S, Roy R, Molinaro AM, Chang SM, et al. Characterization of metabolic, diffusion, and perfusion properties in GBM: contrast-enhancing versus non-enhancing tumor. Transl Oncol. 2017;10(6):895–903.PubMedPubMedCentralCrossRefGoogle Scholar
  63. 63.
    Hu LS, Ning S, Eschbacher JM, Baxter LC, Gaw N, Ranjbar S, et al. Radiogenomics to characterize regional genetic heterogeneity in glioblastoma. Neuro-Oncology. 2017;19(1):128–37.PubMedCrossRefGoogle Scholar
  64. 64.
    Gill BJ, Pisapia DJ, Malone HR, Goldstein H, Lei L, Sonabend A, et al. MRI-localized biopsies reveal subtype-specific differences in molecular and cellular composition at the margins of glioblastoma. Proc Natl Acad Sci U S A. 2014;111(34):12550–5.PubMedPubMedCentralCrossRefGoogle Scholar
  65. 65.
    Hu LS, Ning S, Eschbacher JM, Gaw N, Dueck AC, Smith KA, et al. Multi-parametric MRI and texture analysis to visualize spatial histologic heterogeneity and tumor extent in glioblastoma. PLoS One. 2015;10(11):e0141506.PubMedPubMedCentralCrossRefGoogle Scholar
  66. 66.
    Barajas RF, Hess CP, Phillips JJ, Von Morze CJ, Yu JP, Chang SM, et al. Super-resolution track density imaging of glioblastoma: histopathologic correlation. AJNR Am J Neuroradiol. 2013;34(7):1319–25.PubMedPubMedCentralCrossRefGoogle Scholar
  67. 67.
    Stadlbauer A, Ganslandt O, Buslei R, Hammen T, Gruber S, Moser E, et al. Gliomas: histopathologic evaluation of changes in directionality and magnitude of water diffusion at diffusion-tensor MR imaging. Radiology. 2006;240(3):803–10.PubMedCrossRefGoogle Scholar
  68. 68.
    Khayal IS, Vandenberg SR, Smith KJ, Cloyd CP, Chang SM, Cha S, et al. MRI apparent diffusion coefficient reflects histopathologic subtype, axonal disruption, and tumor fraction in diffuse-type grade II gliomas. Neuro-Oncology. 2011;13(11):1192–201.PubMedPubMedCentralCrossRefGoogle Scholar
  69. 69.
    Luks TL, McKnight TR, Jalbert LE, Williams A, Neill E, Lobo KA, et al. Relationship of in vivo MR parameters to histopathological and molecular characteristics of newly diagnosed, nonenhancing lower-grade gliomas. Transl Oncol. 2018;11(4):941–9.PubMedPubMedCentralCrossRefGoogle Scholar
  70. 70.
    Hu LS, Eschbacher JM, Dueck AC, Heiserman JE, Liu S, Karis JP, et al. Correlations between perfusion MR imaging cerebral blood volume, microvessel quantification, and clinical outcome using stereotactic analysis in recurrent high-grade glioma. AJNR Am J Neuroradiol. 2012;33(1):69–76.PubMedCrossRefPubMedCentralGoogle Scholar
  71. 71.
    Barajas RF, Hodgson JG, Chang JS, Vandenberg SR, Yeh R-F, Parsa AT, et al. Glioblastoma multiforme regional genetic and cellular expression patterns: influence on anatomic and physiologic MR imaging. Radiology. 2010;254(2):564–76.PubMedPubMedCentralCrossRefGoogle Scholar
  72. 72.
    Jain R, Narang J, Gutierrez J, Schultz LR, Scarpace L, Rosenblum M, et al. Correlation of immunohistologic and perfusion vascular parameters with MR contrast enhancement using image-guided biopsy specimens in gliomas. Acad Radiol. 2011;18(8):955–62.PubMedCrossRefPubMedCentralGoogle Scholar
  73. 73.
    Price SJ, Green HAL, Dean AF, Joseph J, Hutchinson PJ, Gillard JH. Correlation of MR relative cerebral blood volume measurements with cellular density and proliferation in high-grade gliomas: an image-guided biopsy study. AJNR Am J Neuroradiol. 2011;32(3):501–6.PubMedCrossRefPubMedCentralGoogle Scholar
  74. 74.
    Essock-Burns E, Phillips JJ, Molinaro AM, Lupo JM, Cha S, Chang SM, et al. Comparison of DSC-MRI post-processing techniques in predicting microvascular histopathology in patients newly diagnosed with GBM. J Magn Reson Imaging. 2013;38(2):388–400.PubMedCrossRefPubMedCentralGoogle Scholar
  75. 75.
    Jain R, Gutierrez J, Narang J, Scarpace L, Schultz LR, Lemke N, et al. In vivo correlation of tumor blood volume and permeability with histologic and molecular angiogenic markers in gliomas. AJNR Am J Neuroradiol. 2011;32(2):388–94.PubMedCrossRefPubMedCentralGoogle Scholar
  76. 76.
    Ningning D, Haopeng P, Xuefei D, Wenna C, Yan R, Jingsong W, et al. Perfusion imaging of brain gliomas using arterial spin labeling: correlation with histopathological vascular density in MRI-guided biopsies. Neuroradiology. 2017;59(1):51–9.PubMedCrossRefPubMedCentralGoogle Scholar
  77. 77.
    McKnight TR, Lamborn KR, Love TD, Berger MS, Chang S, Dillon WP, et al. Correlation of magnetic resonance spectroscopic and growth characteristics within grades II and III gliomas. J Neurosurg. 2007;106(4):660–6.PubMedCrossRefPubMedCentralGoogle Scholar
  78. 78.
    Cordova JS, Shu H-KG, Liang Z, Gurbani SS, Cooper LAD, Holder CA, et al. Whole-brain spectroscopic MRI biomarkers identify infiltrating margins in glioblastoma patients. Neuro-Oncology. 2016;18(8):1180–9.PubMedPubMedCentralCrossRefGoogle Scholar
  79. 79.
    Ganslandt O, Stadlbauer A, Fahlbusch R, Kamada K, Buslei R, Blumcke I, et al. Proton magnetic resonance spectroscopic imaging integrated into image-guided surgery: correlation to standard magnetic resonance imaging and tumor cell density. Neurosurgery. 2005;56(2 Suppl):291–8; discussion 291.PubMedPubMedCentralGoogle Scholar
  80. 80.
    Elkhaled A, Jalbert L, Constantin A, Yoshihara HAI, Phillips JJ, Molinaro AM, et al. Characterization of metabolites in infiltrating gliomas using ex vivo 1H high-resolution magic angle spinning spectroscopy. NMR Biomed. 2014;27(5):578–93.PubMedPubMedCentralCrossRefGoogle Scholar
  81. 81.
    Jalbert LE, Elkhaled A, Phillips JJ, Neill E, Williams A, Crane JC, et al. Metabolic profiling of IDH mutation and malignant progression in infiltrating glioma. Sci Rep. 2017;7:44792.PubMedPubMedCentralCrossRefGoogle Scholar
  82. 82.
    Jalbert LE, Neill E, Phillips JJ, Lupo JM, Olson MP, Molinaro AM, et al. Magnetic resonance analysis of malignant transformation in recurrent glioma. Neuro-Oncology. 2016;18(8):1169–79.PubMedPubMedCentralCrossRefGoogle Scholar
  83. 83.
    Constantin A, Elkhaled A, Jalbert L, Srinivasan R, Cha S, Chang SM, et al. Identifying malignant transformations in recurrent low grade gliomas using high resolution magic angle spinning spectroscopy. Artif Intell Med. 2012;55(1):61–70.PubMedPubMedCentralCrossRefGoogle Scholar
  84. 84.
    Hu LS, Eschbacher JM, Heiserman JE, Dueck AC, Shapiro WR, Liu S, et al. Reevaluating the imaging definition of tumor progression: perfusion MRI quantifies recurrent glioblastoma tumor fraction, pseudoprogression, and radiation necrosis to predict survival. Neuro-Oncology. 2012;14(7):919–30.PubMedPubMedCentralCrossRefGoogle Scholar
  85. 85.
    Barajas RF, Butowski NA, Phillips JJ, Aghi MK, Berger MS, Chang SM, et al. The development of reduced diffusion following bevacizumab therapy identifies regions of recurrent disease in patients with high-grade glioma. Acad Radiol. 2016;23(9):1073–82.PubMedPubMedCentralCrossRefGoogle Scholar
  86. 86.
    LaViolette PS, Mickevicius NJ, Cochran EJ, Rand SD, Connelly J, Bovi JA, et al. Precise ex vivo histological validation of heightened cellularity and diffusion-restricted necrosis in regions of dark apparent diffusion coefficient in 7 cases of high-grade glioma. Neuro-Oncology. 2014;16(12):1599–606.PubMedPubMedCentralCrossRefGoogle Scholar
  87. 87.
    Rock JP, Scarpace L, Hearshen D, Gutierrez J, Fisher JL, Rosenblum M, et al. Associations among magnetic resonance spectroscopy, apparent diffusion coefficients, and image-guided histopathology with special attention to radiation necrosis. Neurosurgery. 2004;54(5):1111–7; discussion 1117.PubMedCrossRefPubMedCentralGoogle Scholar
  88. 88.
    Rabinov JD, Lee PL, Barker FG, Louis DN, Harsh GR, Cosgrove GR, et al. In vivo 3-T MR spectroscopy in the distinction of recurrent glioma versus radiation effects: initial experience. Radiology. 2002;225(3):871–9.PubMedCrossRefPubMedCentralGoogle Scholar
  89. 89.
    Srinivasan R, Phillips JJ, Vandenberg SR, Polley M-YC, Bourne G, Au A, et al. Ex vivo MR spectroscopic measure differentiates tumor from treatment effects in GBM. Neuro-Oncology. 2010;12(11):1152–61.PubMedPubMedCentralCrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2020

Authors and Affiliations

  1. 1.University of California San Francisco, Department of Radiology and Biomedical ImagingSan FranciscoUSA

Personalised recommendations

Cite chapter

Buy options